LGND Ligand Pharmaceuticals Incorporated

86.42
+3.41  (+4%)
Previous Close 83.01
Open 84.31
Price To Book 1.81
Market Cap 1,385,502,465
Shares 16,032,197
Volume 417,934
Short Ratio
Av. Daily Volume 603,089
Stock charts supplied by TradingView

NewsSee all news

  1. LIGAND PHARMACEUTICALS INC General Corporate Statement (Form8) (0000886163-20-000037)

  2. Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of its acquisition of the core assets of Icagen's North Carolina operations. As previously announced, the purchase price was $15 million in

  3. Ligand's Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that today's scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast

  4. Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that senior management will present at two upcoming investor conferences. Management will deliver a company presentation at the Barclays Global

  5. Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

sNDA approval announced June 11, 2018.
KYPROLIS (ASPIRE)
Relapsed Multiple Myeloma
Phase 2a data released March 2, 2018.
RPL554
Cystic fibrosis
FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
FDA approval announced October 1, 2018.
KYPROLIS (ARROW)
Multiple Myeloma
sNDA approved January 17, 2018.
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
Phase 3 trial to be initiated mid-2020.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 top-line data due 1Q 2021.
Sparsentan - DUPLEX
Focal segmental glomerulosclerosis (FSGS)
Phase 2b trial initiation announced November 19, 2019. Phase 2 additional data to be presented at EASL April 17, 2020.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 data did not meet primary endpoint - January 2, 2020.
SB206
Molluscum contagiosum skin infection
FDA Approval announced October 24, 2019.
Baxdela
Community-acquired bacterial pneumonia (CABP)
Phase 3 data due 1H 2022.
Sparsentan
IgA nephropathy
Phase 1 trial ongoing.
APVO436
Acute myeloid leukemia (AML)
Phase 2 data met primary endpoint - August 5, 2019.
RPL554 DPI formulation
Maintenance treatment of COPD
Phase 1 top-line data met primary endpoint - July 10, 2019.
Captisol-enabled (CE) Iohexol program
Contrast-induced Nephropathy
Phase 3 trial to be initiated 2020.
Ensifentrine (RPL554) and tiotropium
Chronic obstructive pulmonary disease (COPD)
Phase 2 MDI single dose data showed a statistically significant increase in lung function. Initiation of multiple dose part of pMDI trial postponed due to the COVID-19 situation.
Ensifentrine (RPL554) - Metered Dose Inhaler
Maintenance treatment of COPD
Phase 3 trial has been initiated by partner CStone Pharmaceuticals.
CS1001
Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.

Latest News

  1. LIGAND PHARMACEUTICALS INC General Corporate Statement (Form8) (0000886163-20-000037)

  2. Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of its acquisition of the core assets of Icagen's North Carolina operations. As previously announced, the purchase price was $15 million in

  3. Ligand's Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that today's scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast

  4. Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that senior management will present at two upcoming investor conferences. Management will deliver a company presentation at the Barclays Global

  5. Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted

  6. Ligand Agrees to Acquire Core Assets, Partnered Programs and Ion Channel Technologies from Icagen

    Transaction Expected to be Immediately Accretive to Revenues and Adjusted EPS Slides to accompany this announcement are posted to Ligand.com Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the signing of

  7. Ligand Reports Fourth Quarter and Full Year 2019 Financial Results

    Conference Call and Webcast with Slides Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2019, and

  8. Ligand's Technologies Support and Enable Potential Coronavirus Treatments

    Partner Gilead Sciences' Captisol®-enabled remdesivir (GS-5734) highlighted in the New England Journal of Medicine for treating the first case of the 2019 novel coronavirus in the United States OmniAb® antibody

  9. Lemelson Capital Management Reports FYE 2019 Results for The Amvona Fund, LP

    Short and Long positions contribute to FYE 2019 net returns of 151 percent1 SHELBURNE, Vt., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Lemelson Capital Management, LLC (LCM), today announced financial results for The Amvona

  10. Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics

    OmniAb technology to be accessed by Pandion for range of discovery programs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion

  11. Ligand to Report 2019 Fourth Quarter and Full Year Financial Results on February 6th

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report 2019 fourth quarter and full year financial results on February 6, 2020. Ligand's CEO John Higgins, President and COO Matt Foehr and

  12. Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine's 2019 Most Influential Corporate Directors

  13. Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand's full OmniAb antibody discovery

  14. Ligand Pharmaceuticals Ranked in Deloitte's 2019 Technology Fast 500™

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it ranked in Deloitte's Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech

  15. Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Presentation at the American Society of Nephrology (ASN) Kidney Week 2019 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE)

  16. Ligand to Participate in the Stephens 2019 Nashville Investment Conference

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to

  17. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /PRNewswire/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that

  18. Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA, Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTCQB:IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem

  19. Ligand Reports Third Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2019 and provided an operating

  20. Ligand to Report Third Quarter 2019 Results on November 5th

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand's CEO John Higgins, President and COO Matt Foehr and Executive Vice

  21. Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand" or "the Company") announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President

  22. ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA, Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV:IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global

  23. Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    COLUMBUS, Ohio, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine